BridgeBio Pharma BBIO Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's total equity?
- BridgeBio Pharma (BBIO) reported total equity of -$2.28B in Q1 2026.
- How has BridgeBio Pharma's total equity changed year-over-year?
- BridgeBio Pharma's total equity decreased by 38.2% year-over-year, from -$1.65B to -$2.28B.
- What is the long-term trend for BridgeBio Pharma's total equity?
- Over 5 years (2020 to 2025), BridgeBio Pharma's total equity has grown at a 104.8% compound annual growth rate (CAGR), from $57.91M to -$2.09B.
- What does total equity mean?
- The total net value of the company belonging to the shareholders.
- How do you interpret total equity?
- A growing trend indicates value creation, while a declining trend may signal operational losses or excessive debt financing.
- How does total equity compare across companies?
- Standardized across all companies; a key metric for assessing overall financial health.